GSK Enters Agreement to Acquire IDRx for $1.15 Billion To Strengthen Cancer Portfolio
GSK Enters Agreement to Acquire IDRx for $1.15 Billion To Strengthen Cancer Portfolio UK pharmaceutical giant GSK has confirmed that it has signed an agreement to acquire the privately-held biotechnology ...